Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced that its U.S. partner Bristol-Myers Squibb has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa study for BL-B01D1, an in-house developed bispecific antibody drug conjugate (ADC), in patients with advanced solid tumors.
The molecule, which targets EGFR and HER3, was the subject of an $8.4 billion licensing agreement signed with Bristol-Myers Squibb at the end of 2023. The deal involved a total of $8.4 billion, with an upfront payment of $800 million. Over 20 clinical trials for the molecule are currently underway in China and the U.S.- Flcube.com
